Ponatinib analogues: Virtual screening, precursor, synthesis, and approaches in the preparation of selected compounds
Ponatinib (AP24534), a chemotherapeutic agent used to treat chronic myeloid leukemia, exhibits its action through the competitive inhibition of BCR-ABL tyrosine kinases. Although it is potent enough to inhibit resistant variants of the enzyme including the T315I mutant, compound point mutations in t...
Saved in:
Main Author: | Padilla, Vince Lambert H. |
---|---|
Format: | text |
Language: | English |
Published: |
Animo Repository
2020
|
Subjects: | |
Online Access: | https://animorepository.dlsu.edu.ph/etd_masteral/6337 https://animorepository.dlsu.edu.ph/cgi/viewcontent.cgi?article=13407&context=etd_masteral |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | De La Salle University |
Language: | English |
Similar Items
-
Chromosomal aberrations and molecular changes in BCR-ABL gene in Chronic Myelogenous Leukemia (CML) patients undergoing chemotherapy
by: Soriano-Abad, Ma. Celeste S.
Published: (2010) -
C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion
by: Hayashi, Y., et al.
Published: (2016) -
Survival of childhood leukemia in Singapore
by: Quah, T.C., et al.
Published: (2013) -
LIPOSOMAL FORMULATION OF RATIONAL COMBINATION OF BIOACTIVE LIPIDS FOR THE TREATMENT OF LEUKEMIA
by: TAN KUAN BOONE
Published: (2013) -
Parenteral glutamine-dipeptide supplementation in acute myeloid leukemia patients receiving chemotherapy : effects on neutrophil functions, prevention of chemotherapy-induced side effects and impact on cost-effectiveness
by: Chuleegone Sornsuvit
Published: (2023)